Pherecydes Pharma

6 articles with Pherecydes Pharma

• Pherecydes Pharma and BIOASTER join forces to explore the use of phage therapy to treat complicated urinary tract infections

  7/16/2019

  Pherecydes Pharma and BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, announce the signing of a collaboration agreement.

• Pherecydes Pharma reports successful patient treatment with bacteriophages

  1/30/2019

  Phage therapy could offer an alternative treatment method in the fight against antimicrobial resistance

• Antibiotic Resistance: Pherecydes Pharma Raises €8.7M ($10.3M)

  1/16/2018

  With this financial support, the company plans to produce phages for compassionate use in accordance with GMP.

• Antibiotic Resistance: Pherecydes Pharma Appoints Guy-Charles Fanneau De La Horie As Chief Executive Officer

  2/22/2016

• A World First: Pherecydes Pharma Launches Multicenter Clinical Study Of Phage Therapy In Serious Burn Victims

  9/9/2015

• Pherecydes Pharma Secures DGA Funding for Evaluating the Use of Bacteriophages Against Infected, Antibiotic Resistant Burns

  1/18/2012